Apellis Pharmaceuticals, Inc. Income Statement

Income Statement Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.37M-2.51M-5.29M250.65M66.56M75.42M396.59M781.37M
Cost of Revenue 0.20M5.64M58.51M117.72M
Gross Profit -0.37M-2.51M-5.29M250.65M66.36M69.79M338.08M663.64M
Operating items
Research & Development 40.30M105.29M220.97M299.92M345.87M387.24M354.39M327.57M
Selling, General & Administrative 10.46M22.64M67.05M139.40M176.77M277.16M500.81M501.05M
Other Operating Expenses 25.05M80.20M5.64M58.51M117.72M
Operating Expenses 50.77M127.92M288.01M464.37M602.84M670.03M913.71M946.35M
Operating Income -50.77M-127.92M-288.01M-213.73M-536.28M-594.61M-517.12M-164.98M
EBIT -50.77M-127.92M-288.01M-213.73M-536.28M-594.61M-517.12M-164.98M
Non-operating items
Interest & Investment Income 0.28M2.96M5.11M4.16M0.42M8.91M20.93M12.77M
Other Non Operating Income -0.14M-0.03M-14.84M-103.03M-97.67M-0.29M-0.73M-2.17M
Non Operating Income -0.14M-0.03M-0.17M22.76M38.68M50.22M42.10M16.79M
Net income details
EBT -50.86M-127.50M-304.71M-343.03M-746.00M-651.50M-526.50M-196.72M
Tax Provisions 1.84M0.35M0.67M2.13M1.16M
Profit After Tax -51.01M-127.50M-304.71M-344.87M-746.35M-652.17M-528.63M-197.88M
Income from Continuing Operations -50.86M-127.50M-304.71M-344.87M-746.35M-652.17M-528.63M-197.88M
Consolidated Net Income -50.86M-127.50M-304.71M-344.87M-746.35M-652.17M-528.63M-197.88M
Income towards Parent Company -50.86M-127.50M-304.71M-344.87M-746.35M-652.17M-528.63M-197.88M
Net Income towards Common Stockholders -50.86M-127.50M-304.71M-344.87M-746.35M-652.17M-528.63M-197.88M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 49.26M50.33M56.24M63.89M75.74M87.30M110.58M118.50M124.39M
Shares Outstanding (Diluted Average) 75.16M84.42M106.11M118.68M123.91M
EBITDA -51.01M-127.62M-304.74M-344.84M-748.33M-650.96M-531.29M-197.64M